『2 Minutes with Joey - PFE Stock News』のカバーアート

2 Minutes with Joey - PFE Stock News

2 Minutes with Joey - PFE Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on Pfizer (PFE) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • PFE Today - Jul 15: Bearishness Sparks Conversations

    PFE Today - Jul 15: Bearishness Sparks Conversations
    2026/07/15
    Hey there! It’s Joey, your friendly longtime investor, breaking down the stock scene for you. Today, we’re talking about Pfizer, and it was a green day for them—up about 1.36%. Not a massive jump, but hey, we’ll take what we can get, right?

    So, what happened? Well, Pfizer managed to bounce back a bit today after a rough patch. After taking a hit recently, the stock saw some nice movement, but let’s be real, it’s still not back to where it wants to be. Volume was pretty low compared to usual, which tells me not a ton of action was happening.

    Now, why did this happen? There’s been a lot of chatter about bearish sentiments surrounding Pfizer and even Gilead Sciences, with some folks thinking this might be a contrarian opportunity. Basically, some investors are looking at the current dip and thinking, "Hey, maybe this is a chance to buy low." But others are still feeling the sting from Pfizer’s earlier 21% slump, making them cautious. Plus, there's buzz about Pfizer having the highest-yielding dividend in the S&P 500, which can be a double-edged sword—great for income, but it raises questions about sustainability.

    Oh, and there was some talk about a competitor, BioCryst Pharmaceuticals, having a rough day, which might’ve helped Pfizer look a little better in comparison. Sometimes it’s just about how you stack up against the competition, right?

    One thing worth keeping an eye on? The ongoing discussions about Pfizer’s dividend. Investors are definitely paying attention to how that plays out, especially with all the recent ups and downs.

    So, that’s the scoop on Pfizer today! It’s a bit of a mixed bag, but at least it’s not a total disaster. Remember, this is just for your info and entertainment—no financial advice here, folks! Catch you later!
    続きを読む 一部表示
    2 分
  • PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer

    PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer
    2026/07/14
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Pfizer today. So, PFE had a red day, dropping about 0.8%. Ouch, right?

    Let’s get into it. Today was a bit rough for Pfizer. The stock got hit as news rolled in about drug pricing deals from Donald Trump that are shaking things up for big pharma. Investors were clearly feeling the weight of that news. Plus, there was a lot of chatter about some disappointing results from a lung cancer trial. That overshadowed Pfizer’s win with Ibrance, which is supposed to be a big deal. So yeah, it seems like people were hitting the sell button pretty fast.

    Now, why all the fuss? Well, it looks like these drug pricing deals could mean tighter profit margins for companies like Pfizer. The market's not really loving that, especially when you throw in a couple of price target cuts from big firms. BMO just slashed their target to $30 from $34, and Guggenheim did something similar, dropping it to $35. That’s not great for investor confidence. And when you mix that with the disappointment from the lung cancer trial, it’s no wonder folks are feeling skittish.

    One thing worth mentioning is that Pfizer did get FDA approval for something recently, but the market’s reaction was pretty muted. It’s like, “Yeah, cool, but what have you done for me lately?” That kind of vibe can really affect how stocks move, and today was a clear example of that.

    So, to wrap it all up: Pfizer’s facing some headwinds with drug pricing changes and trial results that didn’t quite hit the mark. It’s a tough spot, but that’s just how investing goes sometimes. Remember, this is just for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • PFE Today - Jul 13: Price Target Cuts Hit Hard

    PFE Today - Jul 13: Price Target Cuts Hit Hard
    2026/07/13
    Hey there! It's Joey, your friendly investor buddy, breaking down what went down today with Pfizer. So, PFE had a bit of a green day, up about 1.82%. Not too shabby, right?

    But hold on, it wasn’t all sunshine and rainbows. The stock kinda had a rough ride earlier in the week. Today’s uptick was like a small bounce back after some recent price target cuts from analysts. Guggenheim lowered its target to $35, and BMO Capital followed suit, dropping theirs to $30. That’s never a fun thing to hear as a shareholder. People were probably feeling a bit jittery about it.

    Now, let’s talk about the why behind today’s action. Despite those price cuts, Pfizer scored a big win with FDA approval for its Lyme disease vaccine, showing a promising 70% efficacy. That’s incredible news, but it seems like Wall Street wasn’t super excited about it. The reaction was kinda muted, like when you tell your friends about a cool new game and they’re just like, “Yeah, cool.” It’s a bummer when good news doesn’t translate to excitement on the stock side, right?

    And get this—there's a lot going on in the healthcare space right now. While Pfizer's vaccine news is solid, the market's still buzzing about other big players making moves, like Novo Nordisk launching a subscription model for Wegovy. Everyone's trying to figure out how these shifts impact the whole scene.

    So, yeah, that’s the lowdown on Pfizer today. Always a mix of wins and losses in the stock game. Just remember, this is all info for you to chew on, not financial advice or anything. Keep your head up, and I’ll catch you later!
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません